First, I think it's pretty funny that a criticism of safe supply programs is that they give excellent care and excellent wraparound supports, but also, the data that I presented to you from the CMAJ study was before we had SUAP funding for those wraparound supports. The data I reported to you about a 50% reduction in emergency department admissions and the number of infections and a 50% reduction in costs was only from safe supply prescribing. At that time, we had no wraparound supports. That speaks clearly—
On February 26th, 2024. See this statement in context.